Status:
COMPLETED
Efficacy and Safety of Enteric-coated Mycophenolate Sodium in Heart Transplant Recipients
Lead Sponsor:
Novartis Pharmaceuticals
Conditions:
Patients Successfully Completing the 12-month Treatment Period of the Core Study (de Novo Heart Recipients) Who Were Interested of Being Treated With EC-MPS
Eligibility:
All Genders
18-65 years
Phase:
PHASE3
Brief Summary
This purpose of this extension study of patients being treated with EC-MPS is to assess the long term safety of this medication.
Eligibility Criteria
Inclusion
- Patients who were participating in the core study CERL080A2401 and have successfully completed the first 12 months of the core study
Exclusion
- Patients who did not complete the 12-month core study CERL080A2401
- Other protocol-defined inclusion/exclusion criteria may apply.
Key Trial Info
Start Date :
April 1 2003
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00238446
Start Date
April 1 2003
Last Update
February 24 2017
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.